Structure Therapeutics (GPCR) Expected to Announce Earnings on Friday

Structure Therapeutics (NASDAQ:GPCR) will likely be releasing its quarterly earnings results before the market opens on Friday, March 14th. Analysts expect Structure Therapeutics to post earnings of ($0.23) per share for the quarter.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. On average, analysts expect Structure Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Structure Therapeutics Trading Up 4.3 %

NASDAQ:GPCR opened at $21.42 on Thursday. The firm has a market capitalization of $1.23 billion, a PE ratio of -28.95 and a beta of -2.35. The firm’s fifty day simple moving average is $25.60 and its 200 day simple moving average is $32.66. Structure Therapeutics has a 1 year low of $19.39 and a 1 year high of $62.74.

Analyst Upgrades and Downgrades

GPCR has been the subject of a number of research reports. William Blair began coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating for the company. JMP Securities restated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, December 18th. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Finally, Stifel Nicolaus began coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.